HEALTH

Roche Decision Due on Genentech: Investors and many biotechnology executives will be watching this week to see if Switzerland’s Roche Holdings. buys the 35.7% of Genentech stock that it doesn’t already own. Roche has an option to buy the remaining shares in the biotech pioneer by the end of the year for $57.50 a share and must show its hand by Wednesday. “All eyes will be watching to see if (Roche) increases its investment,” says Robert S. Esposito, national director of the life sciences practice at KPMG Peat Marwick. “If they don’t make the investment, it will signal that they believe the real value in the company is letting it maintain its independence and entrepreneurial spirit.”